表2.
pSS合并ALD患者的临床特征
Clinical features in patients with pSS and ALD
| Items | pSS (with ALD) (n=68) | pSS (without ALD) (n=135) | P value |
| pSS, primary Sjögren’s syndrome; ALD, autoimmune liver disease; AMA-M2, anti-mitochondrial M2 antibody; Ig, immunoglobulin; C3, complement 3; WBC, white blood cells; Hb, hemoglobin; PLT, platelet count; ALT, glutamic-pyruvic transaminase; AST, glutamic oxalacetic transaminase; GGT, glutamyl transpeptidase; ALP, alkaline phosphatase; ESSDAI, EULAR Sjögren’s syndrome disease activity index; UCDA, ursodeoxycholic acid. *, the total daily steroid dose was converted to equivalent dose of prednisone. Data are presented as M (P25, P75) or x±s. | |||
| Age/years | 56.6±11.1 | 54.3±13.1 | 0.220 |
| Male/Female | 10/58 | 10/125 | 0.133 |
| Course/months | 12.0 (2.0, 48.0) | 24.0 (6.0, 84.0) | 0.002 |
| Dry mouth score (0-10) | 2.0 (0, 3.0) | 2.0 (1.0, 3.8) | 0.422 |
| Dry eye score (0-10) | 2.0 (0, 2.5) | 2.0 (0, 3.0) | 0.727 |
| Pain score (0-10) | 0 (0, 0.5) | 0 (0, 2.0) | 0.386 |
| Fatigue score (0-10) | 2.0 (0, 3.0) | 2.0 (0, 4.0) | 0.749 |
| Lymphadenopathy (+/-) | 16/52 | 20/115 | 0.248 |
| Glandular swelling (+/-) | 21/47 | 44/91 | 0.874 |
| Arthritis (+/-) | 3/65 | 32/103 | 0.001 |
| Cutaneous involvement (+/-) | 5/63 | 22/113 | 0.077 |
| Lung involvement (+/-) | 15/53 | 34/101 | 0.729 |
| Renal involvement (+/-) | 10/58 | 31/104 | 0.167 |
| AMA-M2 (+/-) | 33/35 | 12/113 | < 0.001 |
| Anti-centromere antibody (+/-) | 16/52 | 14/121 | 0.012 |
| IgG/(g/dL) | 2.11±0.96 | 1.81±0.88 | 0.039 |
| IgM/(g/dL) | 0.15 (0.1, 0.35) | 0.10 (0.06, 0.17) | 0.001 |
| IgA/(g/dL) | 0.33 (0.25, 0.43) | 0.30 (0.19, 0.38) | 0.118 |
| IgG4/(g/dL) | 0.45 (0.16, 0.98) | 0.36 (0.18, 0.64) | 0.521 |
| C3/(mg/dL) | 88.2±33.8 | 99.6±26.0 | 0.011 |
| WBC/(×109/L) | 4.4±2.4 | 5.3±2.8 | 0.022 |
| Hb/(g/L) | 107.7±21.9 | 117.5±19.2 | 0.001 |
| Lymphocytes/(×109/L) | 1.1 (0.8, 1.4) | 1.3 (1.0, 1.7) | 0.007 |
| PLT/(×109/L) | 121.0±67.7 | 194.5±83.7 | < 0.001 |
| ALT/(U/L) | 77.0 (19.5, 218.3) | 14.5 (10.0, 24.0) | < 0.001 |
| AST/(U/L) | 88.0 (39.3, 217.5) | 20.0 (16.0, 26.0) | < 0.001 |
| GGT/(U/L) | 112.0 (51.8, 213.3) | 19.0 (13.0, 32.3) | < 0.001 |
| ALP/(U/L) | 165.2±133.3 | 77.7±47.1 | < 0.001 |
| Total bilirubin/(μmol/L) | 34.5 (13.5, 162.5) | 8.0 (6.0, 11.0) | < 0.001 |
| Direct bilirubin/(μmol/L) | 19.0 (5.0, 93.5) | 3.0 (2.0, 3.3) | < 0.001 |
| Indirect bilirubin/(μmol/L) | 15.5 (9.0, 44.6) | 5.0 (3.8, 8.0) | < 0.001 |
| Liver cirrhosis (+/-) | 27/41 | 0/135 | < 0.001 |
| ESSDAI scores | 3.4±2.1 | 3.4±1.9 | 0.903 |
| UCDA (+/-) | 31/35 | 3/132 | < 0.001 |
| Hepatic protector (+/-) | 32/34 | 5/130 | < 0.001 |
| Steroid dose/(mg daily)* | 0 (0, 20.0) | 5 (0, 25.0) | 0.266 |
| Immunosuppressive agent (+/-) | 7/61 | 10/125 | 0.593 |
| Steroid dose (last follow-up)/mg | 2.5 (0, 5.0) | 2.5 (0, 5.0) | 0.864 |
| Deaths during follow-up | 9 | 4 | 0.011 |